[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626076":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":47,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":18,"overallStatus":67,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exposure to clinical decision support tool","EXPERIMENTAL","Providers will see a best practice alert with an attached order set upon opening the order entry screen in an eligible patient's medical record.",[13],"Other: Best practice alert and order set for CKD",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","NO_INTERVENTION","Providers will not be exposed to the clinical decision support tool when in the medical record of an eligible patient.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Best practice alert and order set for CKD","Providers are exposed to a best practice alert upon opening of the order entry screen in a patient's medical record. The alert informs the provider of the presence of CKD, details the patient's current relevant labs and medications, and provides a list of recommended indicated GDMT for CKD which the patient is currently not prescribed. The alert includes an order set with all indicated medications with additional prescribing information. The alerts additionally includes a link to updated guidelines for GDMT prescription for CKD. Providers will be given the option to dismiss the alert and to indicate reasons for dismissing.",[9],[25],{"name":26,"affiliation":5,"role":27},"Francis P Wilson, MD MSCE","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","203-737-1704","francis.p.wilson@yale.edu",[34],{"facility":35,"status":18,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":18},"Yale New Haven Health","New Haven","Connecticut","06520","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-72.92816,41.30815,{"lat":45,"lon":44},{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100626076","pragmatic-trial-of-messaging-to-providers-about-treatment-of-chronic-kidney-disease-100626076",false,"NCT07430930","Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease","PROMPT-CKD","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years\n2. Diagnosed with CKD defined by an eGFR ≤60 mL\u002Fmin\u002F1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg or eGFR \\>90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg.\n3. Eligible to receive at least 1 of the following CKD GDMT: ACEi\u002FARB, SGLT2i, MRA or GLP-1 RA based on the following criteria.\n4. To receive an ACEi\u002FARB: eGFR ≥15 ml\u002Fmin\u002F1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg\u002Fg).\n5. To receive an SGLT2i: have heart failure (defined by ICD10 code); or T2D; or uACR ≥200 mg\u002Fg; or eGFR ≥20 ml\u002Fmin\u002F1.732.\n6. To receive an MRA: ns-MRA: have an eGFR ≥25 ml\u002Fmin\u002F1.732, diagnosis of T2D, normal serum potassium (≤4.8 mmol\u002FL) and albuminuria (\\>30 mg\u002Fg). s-MRA: have an eGFR ≥45 ml\u002Fmin\u002F1.732 and heart failure, hyperaldosteronism, or refractory hypertension.\n7. To receive a GLP-1 RA: have T2D.\n8. Ability to take oral medication.\n\nExclusion Criteria:\n\n1. Allergy to the GDMT for which the patient is eligible\n2. End-stage kidney disease\n3. CKD stage 5 (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2)\n4. Glomerulonephritis (by ICD-10 code)\n5. Polycystic kidney disease (by ICD-10 code)\n6. History of kidney transplant\n7. End-stage heart failure\n8. Eligible to receive ACEi\u002FARB but having blood pressure \\\u003C110\u002F70 mmHg or have known renal artery stenosis\n9. Eligible to receive SGLT2i but pregnant or breastfeeding, type 1 DM, history of euglycemic diabetic ketoacidosis or Fournier's gangrene based on ICD10 code.\n10. Eligible to receive MRA but serum potassium ≥5 mmol\u002FL, have office SBP \\\u003C100 mmHg, adrenal insufficiency based on ICD10 code or concomitant treatment with CYP3A4 inhibitors (Strong: grapefruit, grapefruit juice, itraconazole. Moderate: erythromycin. Weak: amiodarone).\n11. Eligible to receive GLP-1 RA but pregnant; or found to have personal history of pancreatitis; or personal or family history of medullary thyroid cancer or MEN type 2 based on ICD10 code or gastroparesis based on ICD10 code.\n12. Opted out of EHR-based research.","ALL","18 Years",{"count":59,"type":60},1000,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study is a cluster-randomized clinical trial to evaluate whether a tailored, user-centered, clinical decision support (CDS) tool can positively influence prescriber behavior and increase prescription of guideline-directed medical therapy (GDMT) among patients with Chronic Kidney Disease (CKD) across a single healthcare center.",[66],"Chronic Kidney Diseases","NOT_YET_RECRUITING","2026-05-21",{"date":70,"type":71},"2026-05-26","ACTUAL",{"date":73,"type":60},"2026-06",{"date":75,"type":60},"2028-06",{"name":5,"class":6},1]